Treatments You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Turn on more accessible mode Turn off more accessible mode Skip Ribbon Commands Skip to main content Turn off Animations Turn on Animations Not following Our Services Service Areas BCCDC Public Health Laboratory Clinical Prevention Services Data and Analytic Services Environmental Health Services Immunization Programs and Vaccine Preventable Diseases Population & Public Health Public Health Response Our Clinics Sexually Transmitted Infections Clinics Tuberculosis Clinic Programs Antibiotic Wise BC Observatory for Population & Public Health BC Point of Care HIV Testing Program Chee Mamuk Clinical Prevention Services Epidemiology & Surveillance Community Antimicrobial Stewardship Do Bugs Need Drugs? eLab Handbook Food Protection Services Food Security Food Skills for Families GetCheckedOnline Harm Reduction & Substance Use Services Healthy Built Environment Healthy Eating Hepatitis Education Canada Hepatitis Services I Boost Immunity Immunization Program Injury Prevention Kids Boost Immunity National Collaborating Centre for Environmental Health Population & Public Health Surveillance Prevention Health Promotion Rapid Response Team Rural Remote Indigenous Testing SmartSexResource STI/HIV Services TB Services Tick-borne diseases and climate change Wastewater Surveillance Sentinel Household Surveillance Network Sign up for email updates Health Info Prevention & Public Health Animals & Your Health Antibiotic Resistance Asbestos BC Hepatitis Clinics Climate Change Health Communicable Disease for Housing and Social Service Providers Community Health Dairy Safety Death Cap Mushrooms Decriminalization in BC Fish & Shellfish Safety Food Safety Food Safety & Pregnancy Fruits, Vegetables & Grains Safety Hand Hygiene Health Equity Immunization & Vaccines Indigenous Health Resources Lead & Mercury Meat, Poultry & Eggs Safety Preparing for Cold Weather Events Preparing for Heat Events Radiofrequency Exposure Radon Schools, child care, camps Shellfish Harvesting Safety Vaping Wildfire Smoke Diseases & Conditions Amebiasis Amnesic shellfish poisoning Anthrax Avian Influenza Bacillus cereus Bacterial Vaginosis Botulism Brucellosis California serogroup viruses (CSG) Campylobacter Chickenpox / Varicella Chlamydia Cholera Chronic Wasting Disease Clostridium perfringens COVID-19 Cryptococcal Disease Cryptosporidium Cyclospora Infection Diarrhetic Shellfish Poisoning Diphtheria E.Coli Infection Ebola Enterovirus D68 Epididymitis Giardiasis Gonorrhea Haemophilus Influenzae Type B (Hib) Hantavirus Pulmonary Syndrome (HPS) Hepatitis Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Herpes Simplex Virus HIV/AIDS Human Papillomavirus (HPV) Influenza Japanese Encephalitis Legionnaires Disease Leptospirosis Listeria / Listeriosis Liver Disease Lymphogranuloma Venereum (LGV) Malaria Measles Meningococcal Infection Molluscum Contagiosum Mosquito-borne diseases Mpox MRSA Mumps Non-Gonococcal Urethritis (NGU) Norovirus / Norwalk-like virus Paralytic Shellfish Poisoning Pelvic Inflammatory Disease Plague Pneumococcal Polio Proctitis Pubic Lice Q Fever Rabies Raccoon Roundworm Respiratory Syncytial Virus Rubella Salmonella Infection Scabies Seasonal respiratory Sexually Transmitted Infections (STIs) Shigella Shingles Zoster Staphylococcus aureus Streptococcal Disease, Invasive, Group A Syphilis Tetanus Tick-borne diseases Toxoplasmosis Trichomoniasis Tuberculosis Typhoid Fever (Salmonella Typhi) Vaginitis Vancomycin-Resistant Enterococci (VRE) Vibrio parahaemolyticus West Nile Virus (WNV) Whooping Cough / Pertussis Yeast Yellow Fever Yersinia Infection Zika virus Disease Types Bloodborne Diseases Foodborne & Waterborne Diseases Sexually Transmitted Infections Vaccine Preventable Diseases Viral Diseases Zoonotic diseases Our Research Research Focus About Our Research Grand Rounds Projects Areas of Research Related Projects People Sofia Bartlett Aamir Bharmal Robert Brunham Jane Buxton Stephanie Cleland Eric Coker Victoria Cook Alexis Crabtree Erin Fraser Mark Gilbert Troy Grennan Reka Gustafson Rebecca Hasdell Sarah Henderson Chelsea Himsworth Linda Hoang Catherine Hogan William Hsiao Jia Hu Mike Irvine Naveed Janjua Agatha Jassem James Johnston Kate Jongbloed Mel Krajden Kelley Lee Amee Manges Geoffrey McKee David McVea Sandrine Merette Jessica Moe Muhammad Morshed Anne-Marie Nicol Gina Ogilvie Michael Otterstatter Heather Palis Prital Patel David Patrick Cheryl Peters Ian Pike Natalie Prystajecky Roy Purssell Alnoor Ramji Drona Rasali Caren Rose Shannon Russell Manish Sadarangani Travis Salway Hasina Samji Jat Sandhu Hind Sbihi Inna Sekirov Aaron Shapiro Mayank Singal Danuta Skowronski Amanda Slaunwhite Anya Smith Kate Smolina Kimberly Thomson John Tyson Jason Wong Titus Wong Angela Yao Hong Yu James Zlosnik Students & Trainees About What We Do Accountability Accreditation Annual Reports Client & Stakeholder Feedback Data Access Requests News & Stories Stories Media Enquiries Self-harvested shellfish may cause illness Leadership Purpose, Vision, Values & Teachings Eradicating Indigenous-Specific Racism and Discrimination Apology and Leadership Commitments to Indigenous Peoples Journey to Eradicating Indigenous-Specific Racism Thee eat Initiative Public Health Truths and Context Contact Health Professionals Currently selected Clinical Resources Acute Hepatitis Children Adverse Events Following Immunization Antimicrobial Stewardship CARD System for Vaccination Case Definitions Communicable Disease Control Manual COVID-19 Care High Threat Pathogens Environmental Health Risks Immunization Clinical Resources Immunization print materials Informed Consent for Immunization Lead & Mercury Measles Mpox MRSA Nontuberculous Mycobacteria STI Certified Practice Syphilis Toolkit Tuberculosis Clinical Resources Vaccine Management Vaccine Safety Vaccines in BC Data & Reports Antimicrobial Resistance & Utilization BC COVID-19 SPEAK Dashboard Chronic Disease Dashboard Communicable Diseases Communicable Disease Dashboard Community and School-Based Childhood Immunization Coverage Dashboard COVID-19 Young Adults Drug and Poison Information Centre Dashboard Harm Reduction Client Survey Harm Reduction Reports Health Status Hepatitis C Reports HIV/AIDS Reports Immunization Reports Mortality Context App Respiratory Virus Data Societal Consequences COVID-19 STI Reports Substance Use Harm Reduction Dashboard Tuberculosis Reports Education & Development Antimicrobial Stewardship Conference BC One Health and Zoonoses Symposium BC211 Training Canadian Diarrhetic Shellfish Poisoning Symposium Clinical Prevention Services Webinar Series Grand Rounds Hepatitis C Online Courses HIV Point of Care Testing Online Course HIV Testing Face to Face Workshops HIV Testing Online Course Immunization Courses Immunization Forums Marine Biotoxin Workshop STI Certified Practice Online Course Syphilis Overview Course Tuberculosis Online Courses Networks Healthy Built Environment Alliance Professional Resources BC Pediatric Nutrition Guidelines Dairy Plant Guidelines Dairy Plant Licensing & Inspection Fermented Foods Fish & Shellfish Processing Plant Guidelines Food Donation Guidelines Food Premises Guidelines Food Safety Assessment Food Skills Facilitator Resources Health Equity & Environmental Health Health Equity Indicators Health Equity Videos Health Equity Workshop Healthy Built Environment Linkages Toolkit Heat Event Response Planning Laboratory Services Laboratory Trends Newsletter Meat, Poultry & Eggs Guidelines Norovirus & Marine Water Contamination Pharmacy Public Health Language Guide Radiofrequency Toolkit Sea Surface Temperatures Map Sentinel Indoor Temperature Network Shellfish Harvesting & Control Shellfish Harvesting Sites Status Map Supporting People Experiencing Homelessness Surveillance Forms Wildfire Smoke Response Planning Donate Careers Treatments-covid   It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again. Our Services Service Areas BCCDC Public Health Laboratory Clinical Prevention Services Data and Analytic Services Environmental Health Services Immunization Programs and Vaccine Preventable Diseases Population & Public Health Public Health Response Our Clinics Sexually Transmitted Infections Clinics Tuberculosis Clinic Programs Antibiotic Wise BC Observatory for Population & Public Health BC Point of Care HIV Testing Program Chee Mamuk Clinical Prevention Services Epidemiology & Surveillance Community Antimicrobial Stewardship Do Bugs Need Drugs? eLab Handbook Food Protection Services Food Security Food Skills for Families GetCheckedOnline Harm Reduction & Substance Use Services Healthy Built Environment Healthy Eating Hepatitis Education Canada Hepatitis Services I Boost Immunity Immunization Program Injury Prevention Kids Boost Immunity National Collaborating Centre for Environmental Health Population & Public Health Surveillance Prevention Health Promotion Rapid Response Team Rural Remote Indigenous Testing SmartSexResource STI/HIV Services TB Services Tick-borne diseases and climate change Wastewater Surveillance Sentinel Household Surveillance Network Sign up for email updates Health Info Prevention & Public Health Animals & Your Health Antibiotic Resistance Asbestos BC Hepatitis Clinics Climate Change Health Communicable Disease for Housing and Social Service Providers Community Health Dairy Safety Death Cap Mushrooms Death Cap Mushrooms Map Decriminalization in BC Fish & Shellfish Safety Food Safety Food Safety & Pregnancy Fruits, Vegetables & Grains Safety Hand Hygiene Health Equity Immunization & Vaccines Indigenous Health Resources Lead & Mercury Meat, Poultry & Eggs Safety Preparing for Cold Weather Events Preparing for Heat Events Radiofrequency Exposure Radon Schools, child care, camps Shellfish Harvesting Safety Vaping Wildfire Smoke Diseases & Conditions Amebiasis Amnesic shellfish poisoning Anthrax More Resources Avian Influenza More Resources Bacillus cereus Bacterial Vaginosis More Resources Botulism More Resources Brucellosis More Resources California serogroup viruses (CSG) Campylobacter More Resources Chickenpox / Varicella More Resources Chlamydia More Resources Cholera More Resources Chronic Wasting Disease Clostridium perfringens COVID-19 If You Have COVID-19 About COVID-19 Translated Content Symptoms Variants Prevention & Risks Masks Cleaning and Disinfecting COVID-19 Vaccine How to Find Trusted Information About Vaccines Treatments Rapid Antigen Testing Testing When to get a COVID-19 test Going for a COVID-19 test Where to get a COVID-19 test in BC Test Results Understanding Test Results Types of tests Archived B.C. COVID-19 Data Self-Isolation Close contacts COVID-19 and Children COVID-19 Illness in Children Keeping children safe Babies Seeking medical care Children with Immune Compromise Indigenous Community Resources Cryptococcal Disease More Resources Cryptosporidium More Resources Cyclospora Infection More Resources Diarrhetic Shellfish Poisoning More Resources Diphtheria More Resources E.Coli Infection More Resources Ebola More Resources Enterovirus D68 More Resources Epididymitis More Resources Giardiasis More Resources Gonorrhea More Resources Haemophilus Influenzae Type B (Hib) More Resources Hantavirus Pulmonary Syndrome (HPS) More Resources Hepatitis Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Herpes Simplex Virus More Resources HIV/AIDS More Resources Human Papillomavirus (HPV) Influenza Sentinel Network (SPSN) More Resources Japanese Encephalitis More Resources Legionnaires Disease More Resources Leptospirosis More Resources Listeria / Listeriosis More Resources Liver Disease More Resources Lymphogranuloma Venereum (LGV) Malaria More Resources Measles More Resources Exposures and Self-Assessment Tool Meningococcal Infection More Resources Molluscum Contagiosum More Resources Mosquito-borne diseases Mpox MRSA Mumps More Resources Non-Gonococcal Urethritis (NGU) More Resources Norovirus / Norwalk-like virus Gastrointestinal Disease Outbreak More Resources Paralytic Shellfish Poisoning More Resources Pelvic Inflammatory Disease More Resources Plague More Resources Pneumococcal More Resources Polio More Resources Proctitis More Resources Pubic Lice More Resources Q Fever More Resources Rabies More Resources Raccoon Roundworm More Resources Respiratory Syncytial Virus Rubella More Resources Salmonella Infection Integrated Surveillance of Foodborne Pathogens More Resources Scabies More Resources Seasonal respiratory Getting vaccinated Sexually Transmitted Infections (STIs) STI Medication Handout More Resources Shigella More Resources Shingles Zoster More Resources Staphylococcus aureus Streptococcal Disease, Invasive, Group A More Resources Syphilis More Resources Tetanus More Resources Tick-borne diseases Anaplasmosis Babesiosis Lyme Disease (Borrelia burgdorferi infection) Tick Talk Rocky Mountain Spotted Fever Tick-borne Relapsing Fever Tick Paralysis Tularemia Toxoplasmosis More Resources Trichomoniasis More Resources Tuberculosis TB Germ: A World Traveller TB Patient Stories Translated Content Nontuberculous Mycobacteria Medical Surveillance Typhoid Fever (Salmonella Typhi) More Resources Vaginitis More Resources Vancomycin-Resistant Enterococci (VRE) More Resources Vibrio parahaemolyticus West Nile Virus (WNV) Information for Physicians More Resources Whooping Cough / Pertussis More Resources Yeast More Resources Yellow Fever More Resources Yersinia Infection Zika virus Disease Types Bloodborne Diseases Foodborne & Waterborne Diseases Waterborne Disease and Climate Change Sexually Transmitted Infections Vaccine Preventable Diseases Viral Diseases Zoonotic diseases Reportable Zoonoses Our Research Research Focus About Our Research Grand Rounds Projects Areas of Research Related Projects BC Hepatitis Testers Cohort BC Mix COVID-19 Survey Clinical Prevention Services Research Community STI Testing Survey COVID-19 Research People Sofia Bartlett Aamir Bharmal Robert Brunham Jane Buxton Stephanie Cleland Eric Coker Victoria Cook Alexis Crabtree Erin Fraser Mark Gilbert Troy Grennan Reka Gustafson Rebecca Hasdell Sarah Henderson Chelsea Himsworth Linda Hoang Catherine Hogan William Hsiao Jia Hu Mike Irvine Naveed Janjua Agatha Jassem James Johnston Kate Jongbloed Mel Krajden Kelley Lee Amee Manges Geoffrey McKee David McVea Sandrine Merette Jessica Moe Muhammad Morshed Anne-Marie Nicol Gina Ogilvie Michael Otterstatter Heather Palis Prital Patel David Patrick Cheryl Peters Ian Pike Natalie Prystajecky Roy Purssell Alnoor Ramji Drona Rasali Caren Rose Shannon Russell Manish Sadarangani Travis Salway Hasina Samji Jat Sandhu Hind Sbihi Inna Sekirov Aaron Shapiro Mayank Singal Danuta Skowronski Amanda Slaunwhite Anya Smith Kate Smolina Kimberly Thomson John Tyson Jason Wong Titus Wong Angela Yao Hong Yu James Zlosnik Students & Trainees About What We Do Accountability Accreditation Annual Reports Client & Stakeholder Feedback Data Access Requests News & Stories Stories 2026 2025 2024 2023 2022 2021 Media Enquiries Leadership Purpose, Vision, Values & Teachings Eradicating Indigenous-Specific Racism and Discrimination Apology and Leadership Commitments to Indigenous Peoples Journey to Eradicating Indigenous-Specific Racism Thee eat Initiative Public Health Truths and Context Contact Health Professionals Clinical Resources Acute Hepatitis Children Adverse Events Following Immunization Antimicrobial Stewardship Dental Antimicrobial Stewardship CARD System for Vaccination Case Definitions Acquired Immune Deficiency Syndrome (AIDS) Active Tuberculosis (TB) Acute hepatitis non hepatitis A-E Amebiasis Amnesic Shellfish Poisoning Anaplasmosis Anthrax Avian Influenza Borrelia hermsii Infection (Tick-Borne Relapsing Fever) Babesiosis Botulism Brucellosis California Serogroup Virus (CSGV) Infection Campylobacteriosis Chlamydia Ciguatera COVID-19 (Novel Coronavirus) COVID-19 (Novel Coronavirus) Multi-system inflammatory syndrome in children and adolescents (MIS-C) Creutzfeldt-Jakob Disease Cryptococcus gattii Cryptosporidium Cyclospora Infection (Cyclosporiasis) Cytomegalovirus, Congenital Infection Dengue Diarrhetic Shellfish Poisoning Diphtheria E. coli Ehrlichiosis Giardiasis Gonorrhea H. influenzae Hantavirus Hepatitis A Hepatitis B Infection (HBV) Hepatitis C Infection (HCV) Hepatitis E Human Immunodeficiency Virus (HIV) Influenza - Lab Confirmed Legionnaires' Disease (Legionellosis) Leprosy Leptospirosis Listeria (Listeriosis) Lyme Lymphogranuloma Venereum (LGV) Malaria Measles Meningococcal Disease, Invasive Mpox Mumps Norovirus Paralytic Shellfish Poisoning Pertussis Plague Pneumococcal Disease, invasive Powassan Virus Psittacosis Q Fever Rabies Rocky Mountain Spotted Fever Rubella (German Measles) Rubella, Congenital Infection (CRI) Rubella, Congenital Syndrome (CRS) Salmonella Scombroid Shigella Smallpox Streptococcal Disease, invasive Group A Streptococcal Infection, Neonatal Group B Syphilis Tetanus Toxoplasmosis Trichinosis Tularemia Typhoid & Paratyphoid Fevers Varicella, Congenital Syndrome Vibrio Infection Viral Hemorrhagic Fevers West Nile Virus Yellow Fever Yersinia Zika Communicable Disease Control Manual Admin Circulars 2020-2026 2010-2019 2002-2009 Communicable Disease Control Immunization Manual Immunization of Special Populations Biological Products Infection Control Tuberculosis Manual Sexually Transmitted Infections Surveillance of Reportable Conditions COVID-19 Care COVID-19 Vaccinations Toolkit for Health Professionals COVID-19 Testing Viral Testing Point-of-Care COVID-19 Screening Infection Control Treatments Currently selected Public Health Management Clinical Care Hospital and critical care Long-Term Care Facilities & Assisted Living Pregnancy Pediatrics Dialysis patients Risk Factors for Severe COVID-19 Disease People who use substances Community-Based Health Care Signage & Posters Patient Handouts Health Care Provider Support ImmunizeBC COVID SOPs Education and Training Culturally Safe Care High Threat Pathogens Environmental Health Risks Harm Reduction Clinical Resources Immunization Clinical Resources Immunization print materials Informed Consent for Immunization Lead & Mercury Measles Mpox MRSA Nontuberculous Mycobacteria STI Certified Practice Syphilis Toolkit Tuberculosis Clinical Resources Vaccine Management Vaccine Safety Vaccines in BC Data & Reports Antimicrobial Resistance & Utilization Antimicrobial Resistance Dashboard Antimicrobial Utilization Dashboard BC COVID-19 SPEAK Dashboard Chronic Disease Dashboard Communicable Diseases Communicable Disease Dashboard Community and School-Based Childhood Immunization Coverage Dashboard COVID-19 Young Adults Drug and Poison Information Centre Dashboard Harm Reduction Client Survey Harm Reduction Reports Health Status Canadian Community Health Survey Dashboard Hepatitis C Reports HIV/AIDS Reports Immunization Reports Mortality Context App Respiratory Virus Data Societal Consequences COVID-19 The Project Indigenous Health and Wellness Population Health and Wellness Mental Health and Substance Use Health Care Services Community Support Systems and the Economy Environmental Health Resources STI Reports Substance Use Harm Reduction Dashboard Tuberculosis Reports Education & Development Antimicrobial Stewardship Conference BC One Health and Zoonoses Symposium BC211 Training Canadian Diarrhetic Shellfish Poisoning Symposium Clinical Prevention Services Webinar Series Grand Rounds Hepatitis C Online Courses HIV Point of Care Testing Online Course HIV Testing Face to Face Workshops HIV Testing Online Course Immunization Courses Immunization Competency Course Influenza Immunization Competency Course Seasonal Influenza Update COVID-19 Immunization Competency Course COVID-19 Vaccines Webinar Immunization Communication Course Vaccine Storage and Handling Course Pearls for Immunization Practice Immunization Forums Marine Biotoxin Workshop STI Certified Practice Online Course Syphilis Overview Course Tuberculosis Online Courses Networks Healthy Built Environment Alliance Professional Resources BC Pediatric Nutrition Guidelines Dairy Plant Guidelines Dairy Plant Licensing & Inspection Fermented Foods Fish & Shellfish Processing Plant Guidelines Food Donation Guidelines Food Premises Guidelines Food Safety Assessment Food Skills Facilitator Resources Health Equity & Environmental Health Health Equity Indicators Health Equity Videos Health Equity Workshop Healthy Built Environment Linkages Toolkit Heat Event Response Planning Laboratory Services Sample Collection and Transport Laboratory Memos & Communications Laboratory Trends Newsletter Meat, Poultry & Eggs Guidelines Norovirus & Marine Water Contamination Pharmacy Public Health Language Guide Radiofrequency Toolkit Sea Surface Temperatures Map Sentinel Indoor Temperature Network Shellfish Harvesting & Control Shellfish Harvesting Sites Status Map Supporting People Experiencing Homelessness Surveillance Forms Wildfire Smoke Response Planning Donate Careers Treatments Find information on the use of therapies in the management of adult patients with confirmed COVID-19 across all disease severities (mild to moderate, severe, and critically ill). ShortPageContent ​​​Last updated: May 2025 May 2025 update : New recommendations for remdesivir in severe COVID-19 The CTC has published new recommendations for the use of remdesivir in severe COVID-19. Recommendations for treatment of mild-moderate disease have also been updated with more precise definitions of high-risk patients.  Key infographics and printable materials   Flowchart: In-patient Algorithm for management of COVID-19 (PDF)   - updated April 2025 Table: Summary of key therapeutics for adults with COVID-19 (PDF)  -  updated April 2025 Health Care Provider Information on Paxlovid and remdesivir (PDF)  - updated April 2025 Additional links and resources   Information for patients: Treatment handouts Management of COVID-19 in Pregnant Persons (PDF)  - September 7, 2022   Clinical practice guide and tools Tab Content 1 Various agents have become available in B.C. for the treatment of COVID-19 in mild to moderately ill patients. These therapies include a direct-acting oral combination antiviral nirmatrelvir/ritonavir (Paxlovid) and an IV direct acting antiviral remdesivir (Veklury).  Clinical Practice Guide and tools for managing mild to moderate illness Clinical Practice Guide: Recommendations and Evidence   Clinical Practice Guide: Recommendations, Evidence and Prescribing Tips   -  updated April 2025​ This document provides general guidance on the use of four therapeutic agents for clinicians and supporting evidence. It includes information on: nirmatrelvir/ritonavir (Paxlovid).  remdesivir (Veklury) Clinical Pathway for Treatment of Mild to Moderate COVID-19   Pathway for treatment of mild to moderate COVID‐19 treatment   -  updated April 2025 This document provides a succinct, hyperlinked flowchart that guides clinicians in assessment and treatment of patients with mild to moderate COVID-19.  Practice Tool: Drug-Drug Interactions and Contraindications   Practice Tool: Drug-Drug Interactions and Contraindications  -  updated  May 2024 This document was developed to identify drug-drug interactions and contraindications with nirmatrelvir/ritonavir (Paxlovid), as well as their potential management strategies. Practice Brief: Crushing Nirmatrelvir/ritonavir (Paxlovid)   Practice Brief: Crushing Nirmatrelvir/ritonavir (Paxlovid) - July 4, 2022 Both ritonavir and nirmatrelvir can be split or crushed and mixed with apple sauce, pudding or any common food or liquid including dairy-containing products based on Phase I studies demonstrating that suspensions achieve similar pharmacokinetics to whole tablets. Both ritonavir and nirmatrelvir can be crushed and mixed with water to the desired consistency and considered for administration via feeding tubes; the tube should be flushed with water after administration. There are currently no precise recipes available; standard practices for administering regular powered tablets via feeding tubes should be applied. It may not be appropriate to administer crushed medications through smaller bore feeding tubes where obstruction is a concern (e.g., jejunal or naso-jejunal); consultation with an expert dietician or nursing staff may be required. Due to lack of information pertaining to stability and storage of nirmatrelvir suspension, it is recommended that any suspension made with crushed nirmatrelvir and ritonavir be extemporaneously compounded as single-dose preparation and not as multi-dose liquid. Advanced COVID-19 Treatment Planning Tool   Advanced COVID-19 Treatment Plan   - Updated May 2024 This Action Plan can be used with high-risk patients who are candidates for COVID-19 therapy before they get sick. Patients can follow testing, treatment and public health recommendations contained in the Green, Yellow and Red zones. Handout for health care providers   Health Care Provider Information on Paxlovid and remdesivir  -  Updated April 2025 Overview for health care providers on COVID-19 Therapies: nirmatrelvir/ritonavir (Paxlovid) and remdesivir (Veklury)   Therapies for mild to moderate illness Tab Content 2 Mild to moderate disease refers to patients with COVID-19 symptoms such as cough, nasal congestion, headache, sore throat, taste disturbance, muscle aches, fever and/or malaise who do not require supplemental oxygen support (i.e., have oxygen saturations of ≥ 94% on room air) for COVID-19 illness.  Patients are usually ambulatory and recovering at home; however, patients with mild to moderate COVID-19 may also reside in Long-Term-Care or Assisted Living or be hospitalized for reasons other than to receive respiratory/organ support for COVID-19. For more detailed information, refer to the Clinical Practice Guide  Nirmatrelvir/ritonavir (Paxlovid)   Nirmatrelvir/ritonavir is recommended within 5 days of symptom onset* to patients who test positive for SARS-COV-2, with appreciable symptoms and a non-reassuring presentation and trajectory, who are at an increased risk for hospitalization or progression to severe COVID-19, such as:  Individuals with moderate to severe immunosuppression , due to: Solid organ transplant Active treatment for a hematological malignancy Allogeneic bone marrow or stem cell transplant in the last year Autologous bone marrow or stem cell transplant in the last 6 months Receipt of chimeric antigen receptor (CAR) T-cell therapy in the last 6 months Receipt of anti-CD-20 or B-cell depleting agents in the last 2 years Receipt of moderately immunosuppressive agents Receipt of systemic treatment for cancer, including for solid tumours, in the last 6 months (3 months for hormonal therapy) Moderate to severe primary immunodeficiency Advanced or untreated HIV Individuals ≥60 years who have serious medical conditions , who have been shown to significantly and consistently benefit from antivirals, such as those with: End-stage renal disease (eGFR < 30ml/min or dialysis) Diabetes treated with insulin Severe or end-stage lung conditions such as COPD, asthma, interstitial lung disease, cystic fibrosis, or neurological conditions requiring Bi-Pap or ventilation Severe intellectual or developmental disabilities Rare blood and genetic disorders such as sickle cell disease, thalassemia, urea cycle defects *It is appropriate to allow the addition of adequate time for delivery of medication for those living in remote and rural communities. **Contraindications include end-stage liver disease (Child Pugh C or cirrhosis), hypersensitivity to protease inhibitors, or serious drug-drug interactions that cannot be managed (see Practice Tool: Drug-Drug Interactions and Contraindications for a complete list). Remdesivir (Veklury)   Remdesivir 200mg IV on day 1, followed by 100mg IV on days 2 and 3 (200mg IV on day 1, followed by 100mg IV 48-72 hours later in eGFR <30ml/min) is recommended within 7 days of symptom onset as an alternative to nirmatrelvir/ritonavir if nirmatrelvir/ritonavir cannot be given due to drug-drug interactions or contraindications ( See Practice Tool – Drug Interactions and Contraindications ). Monoclonal antibodies   Monoclonal Antibodies (mAbs) such as sotrovimab are not recommended . Due to reduced binding to Omicron, there are currently no mAbs in Canada that have reliable activity against circulating variants of concern. The role of monoclonal antibodies is limited to combination therapy in refractory or recalcitrant COVID-19 in patients who are severely immunocompromised and remain non-immune despite vaccination. In such cases, mAbs would need to be ordered through the Special Access Program by a clinician with appropriate expertise, and the variant of concern would require genotypic identification so that the activity of the mAb can be confirmed.   Colchicine   Colchicine was evaluated at 0.6 mg PO BID x 3 days, then 0.6 mg daily x 27 days in a large Canadian RCT (COLCORONA) and demonstrated a reduction in progression of COVID-19 and hospitalization in a sub-group of patients with PCR confirmed COVID-19. The trial’s primary endpoint was not statistically significant and impact of colchicine against hospitalizations from Omicron is unclear.  The trial was stopped early; due to decreased power leading to the low certainty of its results, as well as a higher risk of adverse events (diarrhea and blood clots) guidelines (WHO, NIH) do not recommend colchicine.  If colchicine is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values are necessary. Fluvoxamine   Fluvoxamine was evaluated at 100 mg PO BID x 14 days in a Brazilian RCT (TOGETHER) and shown to reduce emergency room visits lasting > 6 hours, a surrogate endpoint for hospitalizations. It did not demonstrate reductions in actual hospitalizations from COVID-19, length of stay or mortality. For every 12 trial participants, one additional patient stopped fluvoxamine prematurely.  Due to low generalizability from a very high event rate during the Delta wave, as well as lack of robust safety data considering that the maximum daily dose was used in the trial, guidelines (e.g., IDSA, NIH) do not recommend the use of fluvoxamine. A Canadian fluvoxamine study (STOP COVID 2) stopped enrolment due to futility.  If fluvoxamine is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values are necessary. Inhaled Corticosteroids   Inhaled corticosteroids budesonide 800 µg twice daily OR ciclesonide 320 µg twice daily for 14 days may be considered within 14 days of symptom onset in adults with mild to moderate lower respiratory track symptoms of COVID-19 (e.g., cough, increased work of breathing or pneumonia) aged ≥65 OR aged ≥50 with underlying health conditions (e.g., heart disease, chronic lung disease, diabetes, stroke or other neurological conditions) who are not candidates for nirmatrelvir/ritonavir, sotrovimab or remdesivir.  Patients should be informed of uncertainty in the benefit of treatment in decreasing symptom severity or progression, and the risks and potential adverse effects.    Ivermectin   Based on the current scientific evidence and best practice guidelines, inclusive of considering retracted publications, the College of Physicians and Surgeons of BC, the College of Pharmacists of BC, the BC College of Nurses and Midwives and the CTC do not approve of the use of ivermectin for either treatment or prophylaxis for COVID-19 and BC registrants must not prescribe it for this purpose. Ivermectin should not be used outside of approved clinical trials. Unproven or Ineffective Therapies   Various therapies have been evaluated to be ineffective and/or unsafe in treatment of mild to moderate COVID-19 and are not recommended outside of clinical trials. These include: Lopinavir/ritonavir (Kaletra) Oseltamivir (Tamiflu) Chloroquine or hydroxychloroquine Ribavirin and interferon Antivirals used for Hepatitis C (e.g., sofosbuvir/ledipasvir) Oral corticosteroids (e.g., dexamethasone) Intravenous Immunoglobulin G (IVIg) Convalescent Plasma Vitamins D and C Acetylsalicylic Acid (ASA, Aspirin) Therapies for severe to critically ill Tab Content 3 Severe disease Severe disease refers to patients with COVID-19 symptoms who require supplemental low-flow oxygen support (i.e., have oxygen saturations of <94% on room air) for COVID-19 illness. Patients are usually hospitalized but not in the Intensive Care Unit; however, patients with severe COVID-19 may also reside in Long-Term-Care or Assisted Living, present to the emergency department, or receive oxygen therapy for COVID-19 at home. Corticosteroids   Dexamethasone 6 mg IV/SC/PO q24h for up to 10 days is strongly recommended (RECOVERY trial), unless higher doses are clinically indicated*. Hydrocortisone 50 mg IV q6h is recommended as an alternative (REMAP-CAP trial). If dexamethasone and hydrocortisone are not available, methylprednisolone 32 mg IV q24h or prednisone 40 mg PO daily are recommended. * e.g., asthma exacerbation, refractory septic shock, history of chronic steroid use, obstetric use for fetal lung maturation Janus Kinase Inhibitors (baricitinib)   Baricitinib 4 mg PO daily (for GFR ≥60 mL/min), or 2 mg PO daily (for GFR 30-59 mL/min), or 2 mg PO every 2nd day (for GFR 15-29 mL/ min) up to 14 days**, or until hospital discharge (whichever occurs first) is recommended (COV-BARRIER, RECOVERY) for patients hospitalized from COVID-19 requiring supplemental oxygen who show signs of systemic inflammation/cytokine storm (e.g., elevated C-reactive protein ≥ 50 mg/L, ferritin ≥ 1000 µg/L). Baricitinib should only be initiated when oxygen support is required due to COVID-19 pneumonia (not from other causes such as heart failure, pulmonary embolism, etc.).  Baricitinib should not be administered to patients with neutrophils <1.0 x 109/L, lymphocytes <0.2 x 109/L, ALT or AST >5 x ULN, GFR<15 mL/min/1.73 m2. Patients who received immunosuppressants (high-dose corticosteroids, biologics, or JAK inhibitors) were generally excluded from RCTs of baricitinib; if baricitinib is being considered in these patients, benefits vs. risks of over-immunosuppression should be assessed on a case-by-case basis. **Early baricitinib discontinuation should be considered in patients who have clinically improved and no longer require supplemental oxygen *Limited data exist on baricitinib in pregnancy. Risks and benefits should be discussed on a case-by-case basis with pregnant patients with severe COVID-19 Interlukin-6 Inhibitors (tocilizumab)   Tocilizumab is not recommended for patients receiving low-flow oxygen support. The RECOVERY trial found a survival benefit of 4% (28-day mortality: tocilizumab 29% vs. usual care 33%) in patients who had CRP >75 mg/L and on low-flow oxygen, non-invasive respiratory support, or invasive mechanical ventilation. However, considering the scarcity of IL-6 blockers in Canada, CTC and CTRAWG recommend prioritizing tocilizumab use only for critically ill patients at this time, which is the population shown to benefit most in both the REMAP and RECOVERY trials. Venous Thromboembolism (VTE) prophylaxis   Therapeutic anticoagulation (LMWH preferred) can be considered in patients without high-risk features for serious bleeding*. It should start within 72 hours of admission and continue for 14 days or until hospital discharge. Patients who decompensate and require organ support while on therapeutic anticoagulation should continue on therapeutic anticoagulation, if the risk of bleeding remains low. Pooled data from RCTs showed that therapeutic anticoagulation with LMWH/UFH significantly reduces major thrombotic events (OR 0.47; 95% CI 0.24-0.90) but may increase major bleeding (OR 1.45; 95% CI 0.77-2.70) compared with lower doses. Organ support-free days alive were significantly increased with therapeutic heparin (OR 1.29; 95% CI 1.07-1.57). Benefit is more likely in those with elevated D-dimer level or additional risk factors for thrombosis. No differences were observed in the need for invasive mechanical ventilation, intracranial hemorrhage or all-cause mortality. *High risk features for bleeding include age ≥75, eGFR less than 30 mL/min, any coagulopathy, platelet count less than 50, use of dual antiplatelet therapy, recent history of serious GI bleed or recent intracranial condition (stroke, neurosurgery, aneurysm, cancer), epidural or spinal catheter.   Remdesivir (Veklury)   Remdesivir is not recommended in patients with severe COVID-19. While remdesivir has demonstrated a small survival (14.6% vs. 16.3%, p=0.03) in the final analysis of SOLIDARITY, this difference was not observed when mortality was lower. Since current mortality is approximately 50% lower than in SOLIDARITY, the benefit of remdesivir is unlikely. Observational trial with positive results no longer show benefit in late Omicron periods when mortality is low and patients have hybrid immunity.  Remdesivir is non-formulary in BC hospitals due to lack of benefit in the general patient population with severe COVID-19. Seek expert consultation before pursuing non-formulary remdesivir for patients who are deteriorating despite optimal therapy, those with excessive risk of mortality (e.g., elderly on rituximab) or those with recurring or recalcitrant severe infection. However, the lack of evidence of benefit of remdesivir in these scenarios need to be seriously considered. Monoclonal Antibodies   Monoclonal antibody combination REGEN-COV 2.4g (casirivimab 1.2g + imdevimab 1.2g) is NO LONGER recommended due to its lack of neutralization activity against Omicron. Other antibodies are currently being evaluated for treatment of seronegative patients with severe COVID-19.  Sotrovimab should not be used as a substitute.   Ivermectin   Based on the current scientific evidence and best practice guidelines, including in consideration of retracted publications, the College of Physicians and Surgeons of BC, the College of Pharmacists of BC, the BC College of Nurses and Midwives and the CTC do not approve of the use of ivermectin for either treatment or prophylaxis for COVID-19 and BC registrants must not prescribe it for this purpose . Ivermectin should not be used outside of approved clinical trials. Unproven or Ineffective Therapies   Various therapies have been evaluated to be ineffective and/or unsafe in treatment of mild to moderate COVID-19 and are not recommended outside of clinical trials. These include: Lopinavir/ritonavir (Kaletra) Oseltamivir (Tamiflu) Chloroquine or hydroxychloroquine Ribavirin and interferon Intravenous Immunoglobulin G (IVIg) Convalescent Plasma Vitamins D and C Acetylsalicylic Acid (ASA, Aspirin) Critically ill Critical disease refers to patients with COVID-19 symptoms who require respiratory support beyond low-flow oxygen such as high-flow oxygen, non-invasive ventilation, mechanical ventilation, and/or vasopressor/inotropic support for COVID-19 illness. Patients are usually hospitalized in the Intensive Care Unit. Corticosteroids   Dexamethasone 6 mg IV/SC/PO q24h for up to 10 days is strongly recommended (RECOVERY trial), unless higher doses are clinically indicated*. Hydrocortisone 50 mg IV q6h is recommended as an alternative (REMAP-CAP trial). If dexamethasone and hydrocortisone are not available, methylprednisolone 32 mg IV q24h or prednisone 40 mg PO daily are recommended. * e.g., asthma exacerbation, refractory septic shock, history of chronic steroid use, obstetric use for fetal lung maturation Interlukin-6 Inhibitors (tocilizumab)   Tocilizumab AND/OR Baricitinib (see baricitinib) are recommended for patients requiring life support due to confirmed COVID-19. This includes high flow oxygen support (e.g., Optiflow) if flow rate > 30 L/min and FiO2 > 0.4 OR invasive or non-invasive ventilation OR vasopressor or inotropic support. While head-to-head comparative data are lacking, the magnitude of benefit of each agent appears equivalent. However, more robust data exist to support the use of tocilizumab. Baricitinib also carries the additional challenges related to gastric access and cytotoxic precautions. The ultimate choice of agent depends on patient characteristics and practical considerations. Patients receiving baricitinib prior to becoming critically ill may stop baricitinib and be switched to a one-time dose of tocilizumab or continue baricitinib. In patients who continue to deteriorate on immunomodulator monotherapy due to COVID-19-related inflammation/cytokine storm, the combination of tocilizumab and baricitinib can be considered as the addition of baricitinib to tocilizumab has been shown to provide an incremental survival benefit of 2.4% (OR 0.79, CI 0.63-0.97; RECOVERY).  Tocilizumab 400 mg IV (single dose) is recommended (REMAP-CAP, RECOVERY). Dose-capping continues to be recommended over 8mg/kg due to a lack of robust drug supply and similar benefits between the two doses seen in observational studies. Tocilizumab should only be initiated when life support is required because of COVID-19 rather than other causes (such as bacterial infection, pulmonary embolism, etc.). Janus Kinase Inhibitors (baricitinib)   Baricitinib 4 mg po daily (for GFR ≥ 60 mL/min) or 2 mg po daily (for GFR 30-59 mL/min) or 2 mg po every 2nd day (for GFR 15-29 mL/min) up to 14 days, or until discharge from hospital (whichever occurs first) is recommended (COV-BARRIER, RECOVERY). Baricitinib should only be initiated when life support is required because of COVID rather than other causes (such as bacterial infection, pulmonary embolism, etc.). Baricitinib should not be administered to patients with neutrophils < 1.0 x 109/L, , lymphocytes < 0.2 x 109/L, , ALT or AST > 5 x ULN, or eGFR < 15 mL/min (or receiving renal replacement therapy). *Limited data exist on baricitinib in pregnancy. Risks and benefits of baricitinib should be discussed on a case-by-case basis with pregnant patients with critical COVID-19 Venous Thromboembolism (VTE) prophylaxis   Prophylactic-intensity dosing of low molecular weight heparin (LMWH) is recommended for VTE prophylaxis in patients who do not have suspected or confirmed VTE (or other indications for therapeutic anticoagulation).  There is a high probability of harm when therapeutic anticoagulation is initiated in patients who have received organ support for greater than 48 hours (n=1074; NIH mpRCT). Patients receiving therapeutic anticoagulation for COVID-19 prior to organ support should REMAIN on therapeutic anticoagulation and continue for up to 14 days or until hospital discharge. Monoclonal Antibodies (e.g., casirivimab-imdevimab)   Monoclonal antibodies (mAbs; Bamlanivimab/etesevimab, REGEN-COV, Sotrovimab, Regdanvimab) are not recommended. An RCT of REGEN-COV in this population was halted due to signals of harm. Regdanvimab and REGEN-COV conditions for use state that it may be associated with worse outcomes in the critically ill. RECOVERY showed no benefit in the subgroup that required organ support. Various guidelines (IDSA, NIH, INESSS) recommend against mAbs in this setting. ​ Remdesivir (Veklury)   Remdesivir is not recommended in patients with critical COVID-19 as it has not demonstrated to improve survival or time to clinical recovery.   Antibiotics   Antibiotic therapy is not routinely recommended for the treatment of COVID-19 pneumonia. If bacterial co-infection is suspected, follow local practice guidelines for CAP, HAP and VAP. Ivermectin   Based on the current scientific evidence and best practice guidelines, including in consideration of retracted publications, the College of Physicians and Surgeons of BC, the College of Pharmacists of BC, the BC College of Nurses and Midwives and the CTC do not approve of the use of ivermectin for either treatment or prophylaxis for COVID-19 and BC registrants must not prescribe it for this purpose. Ivermectin should not be used outside of approved clinical trials.   Unproven or Ineffective Therapies   Various therapies have been evaluated to be ineffective and/or unsafe in treatment of mild to moderate COVID-19 and are not recommended outside of clinical trials. These include: Lopinavir/ritonavir (Kaletra) Oseltamivir (Tamiflu) Chloroquine or hydroxychloroquine Ribavirin and interferon Intravenous Immunoglobulin G (IVIg) Convalescent Plasma Vitamins D and C Acetylsalicylic Acid (ASA, Aspirin) Tab Heading Tab Content 4 3   Content Editor ​Clinical trials and research  COVID-19 Clinical Trials authorized by Health Canada